NIR II Luminescence Imaging for Sentinel Lymph Node and Enhanced Chemo-/Photothermal Therapy for Breast Cancer,Bioconjugate Chemistry

当前位置： X-MOL 学术 › Bioconjugate Chem. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

NIR II Luminescence Imaging for Sentinel Lymph Node and Enhanced Chemo-/Photothermal Therapy for Breast Cancer
Bioconjugate Chemistry ( IF 4.0 ) Pub Date : 2021-09-01 , DOI: 10.1021/acs.bioconjchem.1c00393
Ruiyi Dai ₁ , Xiangrong Peng ₁ , Bi Lin ₁ , Danyang Xu ₁ , Ruichan Lv ₁

Affiliation

In this research, a NIR II luminescence imaging and enhanced chemo-/photothermal therapy system of CuS–DOX–Nd/FA NPs for breast cancer and lymph node tracing under single 808 nm irradiation is proposed. Nd–DTPA molecular cluster with the NIR II imaging effect as the carrier was designed to load the ultrasmall CuS nanoparticles and chemotherapeutic drug doxorubicin hydrochloride (DOX). The composite probe is used for tumor lesion imaging and tracking the breast cancer sentinel lymph nodes with simultaneous chemo-/photothermal therapy (PTT) for breast cancer under the single 808 nm laser. This designed probe not only has high permeability and retention (EPR) targeting effect but also can respond to the tumor microenvironment (TME), realizing more precise and efficient release of DOX at the cancer focus. At the same time, CuS as a drug carrier has a good photothermal therapy effect (photothermal conversion efficiency: 27.9%). The serialized released chemotherapy DOX and synergistic PTT effect can be used to the treat the in situ breast cancer land and simultaneously kill the metastasis cancer. The system made the combined molecular clusters Nd–DTPA achieve NIR II imaging of tumor lesions of breast cancer and lymph node to obtain the integration of diagnosis of the transferred disease for better prognosis. The feasibility of the system had obvious tumor growth inhibition effect with NIR II imaging guided is verified by a series of in vitro and in vivo experiments.

中文翻译：

前哨淋巴结的 NIR II 发光成像和乳腺癌的增强化疗/光热疗法

在这项研究中，提出了一种用于乳腺癌和淋巴结示踪的 CuS-DOX-Nd/FA NPs 的 NIR II 发光成像和增强化疗/光热治疗系统，在单次 808 nm 照射下。设计具有NIR II成像效应的Nd-DTPA分子簇为载体，负载超细CuS纳米颗粒和化疗药物盐酸阿霉素（DOX）。该复合探针用于肿瘤病灶成像并跟踪乳腺癌前哨淋巴结，在单808 nm激光下对乳腺癌进行同步化疗/光热治疗（PTT）。该设计的探针不仅具有高渗透性和保留（EPR）靶向作用，而且可以响应肿瘤微环境（TME），实现DOX在癌灶处更精准、更高效的释放。同时，CuS作为药物载体具有良好的光热治疗效果（光热转换效率：27.9%）。系列化释放的化疗DOX与协同PTT作用可用于治疗原位乳腺癌，同时杀死转移癌。该系统使组合分子簇Nd-DTPA实现乳腺癌肿瘤病灶和淋巴结的NIR II成像，获得转移性疾病的一体化诊断，从而获得更好的预后。通过一系列体外和体内实验验证了该系统在NIR II成像引导下具有明显的肿瘤生长抑制作用的可行性。

更新日期：2021-09-15

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11